Shingles vaccine and survival in lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This study looks at whether getting the shingles vaccine can help people with lung cancer have fewer shingles cases and possibly live longer. Researchers will follow participants over time to see the effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have been diagnosed with lung cancer (any type, any stage).
- You have never received the shingles (herpes zoster) vaccine.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 4 study checks how safe a shingles vaccine (Shingrix, a non-live vaccine) is for adults with lupus. You might be invited if you have lupus and haven’t had certain shingles or chickenpox-related vaccines recently, and if your lupus symptoms and immune health meet the study rules.
This study tests a live-attenuated shingles vaccine as a booster for people who have already had a recombinant shingles vaccine. It aims to see if the booster is safe and helps maintain protection against shingles.
This trial tests a live shingles vaccine to see how well it works and how safe it is. It may help prevent shingles in adults aged 40 and up.
This Phase 1/2 study tests how safe and how well a shingles (varicella zoster) vaccine works in adults living with HIV whose immune status is measured by CD4 count, plus a healthy comparison group. It may help researchers understand whether the vaccine can safely boost protection in people with HIV.
This study tests a new shingles vaccine for people 40 and older. It looks at safety, how well the body responds, and whether it can prevent shingles.
This trial tests a new shingles vaccine for healthy adults 40 and older. It aims to see if the vaccine is safe and helps protect against shingles.
Hear when a new Lung cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.